Merck's New Pricing Pledge Shows Style Over Substance
A 60% price reduction on hepatitis C drug Zepatier sounds impressive, but the drug has been declining and the HCV space overall is shrinking. Another set of 10% reductions come on small-sellers that are now generic.
You may also be interested in...
Lower list prices for Epclusa, Harvoni, and Zepatier might actually boost revenue by reducing 340B discounts, but rebate-eschewing dynamic may not expand beyond them because of different exposures to 340B in other classes – and the pending HHS rebate rule.
“Authorized generics” for Gilead's leading hepatitis C brands stands out from prior, largely symbolic responses to the lower list prices. This is not a political move, but a business one. It is also the clearest demonstration yet of why pricing reforms are necessary if lower list prices are the policy goal.
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.